The program provides access to more than 300 healthcare leaders across 35 hospitals and 20 health systems to support EvoLiver’s US market entry.
Mursla Bio has been selected to join the Association of British HealthTech Industries (ABHI) US Accelerator program to support the commercial launch of EvoLiver, its Food and Drug Administration (FDA)-designated liver cancer surveillance test.
The Cambridge, UK-based company specializes in extracellular vesicle science and aims to improve chronic disease outcomes for at-risk patients. The ABHI program will provide structured access to more than 300 senior healthcare leaders across 35 leading hospitals, 20 health systems, and US insurers.
The program also offers direct operational guidance from Becton Dickinson, Dell Medical School at the University of Texas, and ABHI’s US advisor network. This access is expected to accelerate EvoLiver’s integration into clinical workflows and help convert launch readiness into early adoption across specialist hepatology centers.
Addressing Liver Cancer Detection Gaps
EvoLiver is a blood test designed to improve liver cancer detection in high-risk patients by leveraging hepatocyte-specific extracellular vesicle biology. The test addresses key limitations of standard approaches for liver cancer surveillance.
Liver cancer remains one of the fastest-growing causes of cancer-related mortality in the US, with gaps in both surveillance performance and patient adherence contributing to late diagnosis. Mursla Bio is pursuing a hepatology-led, guideline-aligned commercial strategy, with broader expansion planned over time as additional clinical evidence supports wider coverage and adoption.
The company continues to advance US launch preparations for EvoLiver, including Clinical Laboratory Improvement Amendments lab preparation, engagement with key opinion leaders and clinical societies, and payor dialogue.
Building Commercial Foundations
“Bringing a new test into clinical use depends on reaching the right people across the healthcare system,” says Pierre Arsène, founder and chief executive officer of Mursla Bio, in a release. “This program strengthens those connections while supporting EvoLiver’s early deployment and laying the commercial foundations for our extracellular vesicle diagnostics platform in the US.”
The ABHI US Accelerator program is designed to help British healthtech companies navigate the complex US healthcare market by providing structured introductions to key stakeholders and operational guidance from established industry partners.
Photo caption: EvoLiver blood test
Photo credit: Mursla Bio
We Recommend for You:
